{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T23:24:37Z","timestamp":1793834677955,"version":"4.6.1"},"reference-count":22,"publisher":"American Society of Hematology","issue":"18","license":[{"start":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T00:00:00Z","timestamp":1716336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,9,24]]},"DOI":"10.1182\/bloodadvances.2024013461","type":"journal-article","created":{"date-parts":[[2024,5,22]],"date-time":"2024-05-22T14:57:11Z","timestamp":1716389831000},"page":"4979-4982","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":22,"title":["Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3302-8726","authenticated-orcid":false,"given":"Heinz","family":"Ludwig","sequence":"first","affiliation":[{"name":"1Department of Medicine I, Wilhelminen Cancer Research Institute, Clinic Ottakring, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8397-100X","authenticated-orcid":false,"given":"Nikhil C.","family":"Munshi","sequence":"additional","affiliation":[{"name":"2Dana-Farber Cancer Institute, Department of Medicine and Boston VA Healthcare System, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5133-1422","authenticated-orcid":false,"given":"Evangelos","family":"Terpos","sequence":"additional","affiliation":[{"name":"3Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilvy","family":"Schweitzer","sequence":"additional","affiliation":[{"name":"1Department of Medicine I, Wilhelminen Cancer Research Institute, Clinic Ottakring, Vienna, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3066-1275","authenticated-orcid":false,"given":"Noopur","family":"Raje","sequence":"additional","affiliation":[{"name":"4Department of Hematology\/Oncology, Center for Multiple Myeloma, Massachusetts General Hospital, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1780-8746","authenticated-orcid":false,"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[{"name":"5Hematology Clinic, University Hospital Hotel-Dieu, Nantes, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4165-6869","authenticated-orcid":false,"given":"Ajay","family":"Nooka","sequence":"additional","affiliation":[{"name":"6Department of Hematology and Oncology, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"issue":"3","key":"2024092415211629400_bib1","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/s41375-023-02105-6","article-title":"Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients","volume":"38","author":"Mai","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"2024092415211629400_bib2","doi-asserted-by":"crossref","first-page":"E349","DOI":"10.1002\/ajh.27071","article-title":"Increased risk of infection reporting with anti-BCMA bispecific monoclonal antibodies in multiple myeloma: a worldwide pharmacovigilance study","volume":"98","author":"Contejean","year":"2023","journal-title":"Am J Hematol"},{"issue":"10","key":"2024092415211629400_bib3","doi-asserted-by":"crossref","first-page":"e2238961","DOI":"10.1001\/jamanetworkopen.2022.38961","article-title":"Kinetics of humoral immunodeficiency with bispecific antibody therapy in relapsed refractory multiple myeloma","volume":"5","author":"Hammons","year":"2022","journal-title":"JAMA Netw Open"},{"key":"2024092415211629400_bib4","doi-asserted-by":"crossref","first-page":"112926","DOI":"10.1016\/j.ejca.2023.05.014","article-title":"Infection rates are high across the multiple myeloma continuum, not just with bispecific antibodies","volume":"189","author":"Rubinstein","year":"2023","journal-title":"Eur J Cancer"},{"issue":"6","key":"2024092415211629400_bib5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"issue":"suppl 16","key":"2024092415211629400_bib6","doi-asserted-by":"crossref","first-page":"8036","DOI":"10.1200\/JCO.2023.41.16_suppl.8036","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"41","author":"Schinke","year":"2023","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"2024092415211629400_bib7","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"2024092415211629400_bib8","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"issue":"9","key":"2024092415211629400_bib9","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 magnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"Suppl 1","key":"2024092415211629400_bib10","doi-asserted-by":"crossref","first-page":"4746","DOI":"10.1182\/blood-2023-177968","article-title":"Patterns of response to 200\u00a0mg linvoseltamab in patients with relapsed\/refractory multiple myeloma: longer follow-up of the linker-MM1 study","volume":"142","author":"Jagannath","year":"2023","journal-title":"Blood"},{"issue":"Suppl 1","key":"2024092415211629400_bib11","doi-asserted-by":"crossref","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of ABB-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"issue":"S3","key":"2024092415211629400_bib12","doi-asserted-by":"crossref","first-page":"e1220745","DOI":"10.1097\/01.HS9.0000970436.12207.45","article-title":"Alnuctamab (Alnuc; BMS-986349; CC-93269), a BCMA\u00a0\u00d7 CD3 T-cell engager in patients (pts) with relapsed\/refractory multiple myeloma (RRMM) : latest results from a phase 1 first in human clinical study","volume":"7","author":"Wong","year":"2023","journal-title":"Hemasphere"},{"issue":"Suppl 2","key":"2024092415211629400_bib13","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/S2152-2650(23)01572-0","article-title":"Efficacy of forimtamig, a GPRC5DxCD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): analysis of patient- and disease-related factors associated with responses","volume":"23","author":"Harrison","year":"2023","journal-title":"Clinical Lymphoma Myeloma and Leukemia"},{"issue":"Suppl 1","key":"2024092415211629400_bib14","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"issue":"13","key":"2024092415211629400_bib15","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"issue":"3","key":"2024092415211629400_bib16","doi-asserted-by":"crossref","first-page":"906","DOI":"10.3324\/haematol.2023.283590","article-title":"The changing spectrum of infection with BCMA and GPRC5D targeting bispecific antibody (bsAb) therapy in patients with relapsed refractory multiple myeloma","volume":"109","author":"Hammons","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"2024092415211629400_bib17","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1177\/0145445516673998","article-title":"Intercoder reliability and validity of webplotdigitizer in extracting graphed data","volume":"41","author":"Drevon","year":"2017","journal-title":"Behav Modif"},{"key":"2024092415211629400_bib18","doi-asserted-by":"crossref","first-page":"e073725","DOI":"10.1136\/bmj-2022-073725","article-title":"CONSORT Harms 2022 statement, explanation, and elaboration: updated guideline for the reporting of harms in randomised trials","volume":"381","author":"Junqueira","year":"2023","journal-title":"BMJ"},{"issue":"1","key":"2024092415211629400_bib19","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"issue":"6","key":"2024092415211629400_bib20","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1038\/s41375-018-0133-x","article-title":"A\u00a0predictive model for risk of early grade \u2265\u00a03 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial","volume":"32","author":"Dumontet","year":"2018","journal-title":"Leukemia"},{"issue":"18","key":"2024092415211629400_bib21","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.1182\/bloodadvances.2023010524","article-title":"Respiratory infections predominate after day 100 following B-cell maturation antigen-directed CAR T-cell therapy","volume":"7","author":"Little","year":"2023","journal-title":"Blood Adv"},{"issue":"4","key":"2024092415211629400_bib22","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.cll.2020.08.003","article-title":"Clinical pathogen genomics","volume":"40","author":"Cameron","year":"2020","journal-title":"Clin Lab Med"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4979\/2243779\/blooda_adv-2024-013461-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/18\/4979\/2243779\/blooda_adv-2024-013461-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T11:21:27Z","timestamp":1727176887000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/18\/4979\/516184\/Proposal-for-harmonizing-the-reporting-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":22,"journal-issue":{"issue":"18","published-print":{"date-parts":[[2024,9,24]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024013461","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]}}}